TW202143970A - 用於治療高風險之非肌肉侵犯性膀胱癌的fgfr酪胺酸激酶抑制劑 - Google Patents
用於治療高風險之非肌肉侵犯性膀胱癌的fgfr酪胺酸激酶抑制劑 Download PDFInfo
- Publication number
- TW202143970A TW202143970A TW110105372A TW110105372A TW202143970A TW 202143970 A TW202143970 A TW 202143970A TW 110105372 A TW110105372 A TW 110105372A TW 110105372 A TW110105372 A TW 110105372A TW 202143970 A TW202143970 A TW 202143970A
- Authority
- TW
- Taiwan
- Prior art keywords
- fgfr
- inhibitor
- patient
- fgfr3
- erdatinib
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975547P | 2020-02-12 | 2020-02-12 | |
| US62/975,547 | 2020-02-12 | ||
| US202063018914P | 2020-05-01 | 2020-05-01 | |
| US63/018,914 | 2020-05-01 | ||
| US202063118475P | 2020-11-25 | 2020-11-25 | |
| US63/118,475 | 2020-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202143970A true TW202143970A (zh) | 2021-12-01 |
Family
ID=74666675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110105372A TW202143970A (zh) | 2020-02-12 | 2021-02-17 | 用於治療高風險之非肌肉侵犯性膀胱癌的fgfr酪胺酸激酶抑制劑 |
Country Status (14)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312063A (en) * | 2021-10-12 | 2024-06-01 | Taris Biomedical Llc | Ardafitinib formulations and systems for intravesical administration |
| JP2025506402A (ja) * | 2022-02-04 | 2025-03-11 | ヤンセン ファーマシューティカ エヌ.ベー. | 転移性去勢抵抗性前立腺癌及びhrr変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン+プレドニゾン |
| WO2023159216A1 (en) * | 2022-02-18 | 2023-08-24 | Taris Biomedical Llc | Erdafitinib formulations and osmotic systems for intravesical administration |
| IL322667A (en) * | 2023-02-13 | 2025-10-01 | Taris Biomedical Llc | Ardepitinib for intravesical administration for use in the treatment of bladder cancer |
| KR20250148646A (ko) * | 2023-02-13 | 2025-10-14 | 얀센 파마슈티카 엔브이 | 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제 |
| CN120731077A (zh) * | 2023-02-17 | 2025-09-30 | 塔里斯生物医药公司 | 膀胱内施用厄达替尼以用于治疗膀胱癌 |
| CN121891539A (zh) * | 2026-02-06 | 2026-04-21 | 深圳大学 | 一种靶向iCAFs亚群的FGF2抑制剂组合物及其在膀胱癌防治中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| SG11201702381QA (en) * | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| TWI719960B (zh) * | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| CA3049737A1 (en) * | 2017-02-06 | 2018-08-09 | Janssen Pharmaceutica Nv | Cancer treatment |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2021
- 2021-02-11 PH PH1/2022/552093A patent/PH12022552093A1/en unknown
- 2021-02-11 MX MX2022009905A patent/MX2022009905A/es unknown
- 2021-02-11 EP EP21706187.8A patent/EP4103185A1/en active Pending
- 2021-02-11 CN CN202180014162.9A patent/CN115103678A/zh active Pending
- 2021-02-11 AU AU2021220285A patent/AU2021220285A1/en active Pending
- 2021-02-11 CA CA3162962A patent/CA3162962A1/en active Pending
- 2021-02-11 BR BR112022015827A patent/BR112022015827A2/pt unknown
- 2021-02-11 KR KR1020227031209A patent/KR20220140781A/ko active Pending
- 2021-02-11 JP JP2022548599A patent/JP2023513704A/ja not_active Withdrawn
- 2021-02-11 IL IL295514A patent/IL295514A/en unknown
- 2021-02-11 US US17/904,139 patent/US20230110113A1/en active Pending
- 2021-02-11 WO PCT/EP2021/053385 patent/WO2021160764A1/en not_active Ceased
- 2021-02-17 TW TW110105372A patent/TW202143970A/zh unknown
-
2022
- 2022-08-09 JO JOP/2022/0182A patent/JOP20220182A1/ar unknown
-
2026
- 2026-03-04 JP JP2026034354A patent/JP2026097934A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023513704A (ja) | 2023-04-03 |
| PH12022552093A1 (en) | 2023-11-29 |
| JOP20220182A1 (ar) | 2023-01-30 |
| KR20220140781A (ko) | 2022-10-18 |
| MX2022009905A (es) | 2022-08-25 |
| JP2026097934A (ja) | 2026-06-16 |
| CN115103678A (zh) | 2022-09-23 |
| EP4103185A1 (en) | 2022-12-21 |
| CA3162962A1 (en) | 2021-08-19 |
| WO2021160764A1 (en) | 2021-08-19 |
| IL295514A (en) | 2022-10-01 |
| US20230110113A1 (en) | 2023-04-13 |
| AU2021220285A1 (en) | 2022-10-06 |
| BR112022015827A2 (pt) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230110113A1 (en) | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer | |
| AU2020253054B2 (en) | FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| JP2025156297A (ja) | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 | |
| JP2015531763A5 (cg-RX-API-DMAC7.html) | ||
| US20250000858A1 (en) | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors | |
| TW202448471A (zh) | 用於治療高風險非肌層浸潤性膀胱癌之fgfr酪胺酸激酶抑制劑 | |
| HK40081735A (en) | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer | |
| HK40064235A (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| HK40126446A (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| HK40064232A (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| EA052400B1 (ru) | Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы |